Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1438.75
-2.95 (-0.20%)
< Home < Back

Cipla receives Establishment Inspection Report from USFDA for Indore facility

Date: 13-10-2016

Cipla has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore facility indicating formal closure of the USFDA inspection conducted in July/August, 2015.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.